Arcus Biosciences (RCUS) Profit After Tax Growth (3y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 33.04% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.60% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -154.28% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.53% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 47.10% |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - | -16.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.96% |
| Dec 31, 2025 | -16.52% |
| Sep 30, 2025 | -27.59% |
| Mar 31, 2025 | -18.10% |
| Dec 31, 2024 | -32.69% |
| Sep 30, 2024 | -5.67% |
| Jun 30, 2024 | -6.97% |
| Mar 31, 2024 | 61.95% |
| Dec 31, 2023 | -16.03% |
| Sep 30, 2023 | -244.73% |
| Jun 30, 2023 | -18.50% |
| Mar 31, 2023 | -42.32% |
| Dec 31, 2022 | -59.22% |
| Sep 30, 2022 | -42.74% |
| Jun 30, 2022 | -33.61% |
| Mar 31, 2022 | -56.71% |
| Dec 31, 2021 | 191.37% |
| Sep 30, 2021 | -93.20% |
| Jun 30, 2021 | -77.73% |
| Mar 31, 2021 | -77.62% |
| Dec 31, 2020 | -57.75% |
| Sep 30, 2020 | 27.63% |
| Jun 30, 2020 | -67.74% |
| Mar 31, 2020 | -56.79% |